Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Filana Therapeutics (NASDAQ: FLNA) reported 2025 results and a business update focused on its TSC-related epilepsy program and capital efficiency.The company posted a net loss of $91.0 million ($1.88 per share) for 2025, year-end cash of $95.5 million and estimates cash of $47–$50 million at June 30, 2026. Filana is addressing FDA requests tied to a December 2025 clinical hold and expects to submit a response as soon as practicable.

#FLNA Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/FLNA/filana-therape...

Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. Filana Therapeutics (NASDAQ: FLNA) is the new corporate name formerly known as Cassava Sciences, effective March 11, 2026.The rebranding aligns the company with its strategic focus on developing medicines that modulate the filamin A protein to address CNS disorders, including Tuberous Sclerosis Complex-related epilepsy. The updated website is available at https://www.filanatx.com.

#FLNA Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.

www.stocktitan.net/news/FLNA/cassava-scienc...

Welcome to Bluesky @vangroovymom.bsky.social 🦋

I have added you to the Rare Genetic Epilepsies Starter Pack 🧠🧬
#DCX #FLNA #PVNH